 | | Vol. 13.19 – 27 May, 2022 |
| |
|
|
| Researchers used ATAC-seq, RNA-seq, and DNA sequencing to investigate 22 organoids, six patient-derived xenografts, and 12 cell lines.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) was found and confirmed to be highly expressed in the prostate cancer (PCa) tissues and cells, and knock-down of DYRK2 remarkably reduced PCa burden in vitro and in vivo.
[Nature Communications] |
|
|
|
| Scientists evaluated if the cell surface protein CDCP1 could be exploited to treat metastatic CRPC with radioligand therapy, including in PSMA low subsets.
[Clinical Cancer Research] |
|
|
|
| Loss of miR-30e expression in prostate tumors, that, when restored, led to cell cycle arrest, induction of apoptosis, improved drug sensitivity of prostate cancer cells, and reduced tumor progression in xenograft models.
[Molecular Oncology] |
|
|
|
| Antioxidant, anticancer and anti-inflammatory activities were evaluated by ABTS-assay, prostate and cervical carcinoma human cell lines and carrageenan-induced rat paw edema model, respectively.
[Scientific Reports] |
|
|
|
| Using pharmacologic reactive oxygen species (ROS) inhibitors and NADPH oxidase 2-null neutrophils, investigators found that ROS depletion specifically suppressed growth of androgen-insensitive prostate cancer cells.
[Clinical & Experimental Metastasis] |
|
|
|
| The Monascus purpureus (MTCC 369) extracted biopigment produced by solid-state fermentation was evaluated for its therapeutic potential using human prostate LNCaP cells.
[Journal of Food Biochemistry] |
|
|
|
| Molecular changes due to the anticancer impact of Brassica oleracea var. acephala on PC3 were involved in the induction of Nrf2 antioxidant pathway and apoptosis and inhibition of inflammation.
[Molecular Biology Reports] |
|
|
|
| MIR22HG and microRNA-9-3p expressions in prostate cancer cells were examined with the use of quantitative real-time PCR.
[Bioengineered] |
|
|
|
| A luciferase reporter assay revealed that MNX1 Antisense RNA 1 (MNX1‑AS1) could target miR‑2113 and negatively interacted with miR‑2113 in prostate cancer cells.
[Molecular Medicine Reports] |
|  |
|
|
|
| The authors assessed different combination treatments for metastatic hormone-sensitive prostate cancer.
[European Urology] |
|
|
|
| Scientists review the molecular mechanisms underlying the emergence of neuroendocrine prostate cancer (NEPC) and provide insights into the future perspectives on potential therapeutic strategies for NEPC.
[Seminars in Cancer Biology] |
|
|
|
|
| MDxHealth SA announced that Palmetto GBA has finalized a foundational Local Coverage Determination (LCD) for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer that covers the indication for our SelectMDx® for Prostate Cancer test.
[MDxHealth SA] |
|
|
|
|
| September 7 – 11, 2022
Woods Hole, Massachusetts, United States |
|
|
|
|
|
| | CRUK Manchester Institute – Manchester, United Kingdom |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| | Marlene and Stewart Greenebaum Comprehensive Cancer Center – Baltimore, Maryland, United States |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
